New hope for hard-to-treat breast cancer: SYS6010 enters phase 3 trial
NCT ID NCT07406542
First seen Feb 13, 2026 · Last updated May 08, 2026 · Updated 12 times
Summary
This study tests a new drug called SYS6010 against standard chemotherapy for people with a specific type of advanced breast cancer (HER2-negative, EGFR-positive) that has come back or spread. About 400 adults aged 18-75 who have already tried 1-2 chemotherapy treatments will be randomly assigned to receive either SYS6010 or a standard chemo drug. The main goal is to see if SYS6010 can delay cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.